Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Altered chromosomal topology drives oncogenic programs in SDH-deficient GIST.

Flavahan WA, Drier Y, Johnstone SE, Hemming ML, Tarjan DR, Hegazi E, Shareef SJ, Javed NM, Raut CP, Eschle BK, Gokhale PC, Hornick JL, Sicinska ET, Demetri GD, Bernstein BE.

Nature. 2019 Oct 16. doi: 10.1038/s41586-019-1668-3. [Epub ahead of print]

PMID:
31618758
2.

Evaluation of ERK as a therapeutic target in acute myelogenous leukemia.

Weisberg E, Meng C, Case A, Sattler M, Tiv HL, Gokhale PC, Buhrlage S, Wang J, Gray N, Stone R, Liu S, Bhagwat SV, Tiu RV, Adamia S, Griffin JD.

Leukemia. 2019 Aug 27. doi: 10.1038/s41375-019-0552-3. [Epub ahead of print] No abstract available.

PMID:
31455850
3.

Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.

Weisberg E, Meng C, Case AE, Sattler M, Tiv HL, Gokhale PC, Buhrlage SJ, Liu X, Yang J, Wang J, Gray N, Stone RM, Adamia S, Dubreuil P, Letard S, Griffin JD.

Br J Haematol. 2019 Jul 15. doi: 10.1111/bjh.16092. [Epub ahead of print]

PMID:
31309543
4.

Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma.

Bandopadhayay P, Piccioni F, O'Rourke R, Ho P, Gonzalez EM, Buchan G, Qian K, Gionet G, Girard E, Coxon M, Rees MG, Brenan L, Dubois F, Shapira O, Greenwald NF, Pages M, Balboni Iniguez A, Paolella BR, Meng A, Sinai C, Roti G, Dharia NV, Creech A, Tanenbaum B, Khadka P, Tracy A, Tiv HL, Hong AL, Coy S, Rashid R, Lin JR, Cowley GS, Lam FC, Goodale A, Lee Y, Schoolcraft K, Vazquez F, Hahn WC, Tsherniak A, Bradner JE, Yaffe MB, Milde T, Pfister SM, Qi J, Schenone M, Carr SA, Ligon KL, Kieran MW, Santagata S, Olson JM, Gokhale PC, Jaffe JD, Root DE, Stegmaier K, Johannessen CM, Beroukhim R.

Nat Commun. 2019 Jun 3;10(1):2400. doi: 10.1038/s41467-019-10307-9.

5.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Ghandi M, Huang FW, Jané-Valbuena J, Kryukov GV, Lo CC, McDonald ER 3rd, Barretina J, Gelfand ET, Bielski CM, Li H, Hu K, Andreev-Drakhlin AY, Kim J, Hess JM, Haas BJ, Aguet F, Weir BA, Rothberg MV, Paolella BR, Lawrence MS, Akbani R, Lu Y, Tiv HL, Gokhale PC, de Weck A, Mansour AA, Oh C, Shih J, Hadi K, Rosen Y, Bistline J, Venkatesan K, Reddy A, Sonkin D, Liu M, Lehar J, Korn JM, Porter DA, Jones MD, Golji J, Caponigro G, Taylor JE, Dunning CM, Creech AL, Warren AC, McFarland JM, Zamanighomi M, Kauffmann A, Stransky N, Imielinski M, Maruvka YE, Cherniack AD, Tsherniak A, Vazquez F, Jaffe JD, Lane AA, Weinstock DM, Johannessen CM, Morrissey MP, Stegmeier F, Schlegel R, Hahn WC, Getz G, Mills GB, Boehm JS, Golub TR, Garraway LA, Sellers WR.

Nature. 2019 May;569(7757):503-508. doi: 10.1038/s41586-019-1186-3. Epub 2019 May 8.

PMID:
31068700
6.

Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition.

Hong AL, Tseng YY, Wala JA, Kim WJ, Kynnap BD, Doshi MB, Kugener G, Sandoval GJ, Howard TP, Li J, Yang X, Tillgren M, Ghandi M, Sayeed A, Deasy R, Ward A, McSteen B, Labella KM, Keskula P, Tracy A, Connor C, Clinton CM, Church AJ, Crompton BD, Janeway KA, Van Hare B, Sandak D, Gjoerup O, Bandopadhayay P, Clemons PA, Schreiber SL, Root DE, Gokhale PC, Chi SN, Mullen EA, Roberts CW, Kadoch C, Beroukhim R, Ligon KL, Boehm JS, Hahn WC.

Elife. 2019 Mar 12;8. pii: e44161. doi: 10.7554/eLife.44161.

7.

MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors.

Howard TP, Arnoff TE, Song MR, Giacomelli AO, Wang X, Hong AL, Dharia NV, Wang S, Vazquez F, Pham MT, Morgan AM, Wachter F, Bird GH, Kugener G, Oberlick EM, Rees MG, Tiv HL, Hwang JH, Walsh KH, Cook A, Krill-Burger JM, Tsherniak A, Gokhale PC, Park PJ, Stegmaier K, Walensky LD, Hahn WC, Roberts CWM.

Cancer Res. 2019 May 1;79(9):2404-2414. doi: 10.1158/0008-5472.CAN-18-3066. Epub 2019 Feb 12.

PMID:
30755442
8.

Dual inhibition of MDM2 and MDM4 in virus-positive Merkel cell carcinoma enhances the p53 response.

Park DE, Cheng J, Berrios C, Montero J, Cortés-Cros M, Ferretti S, Arora R, Tillgren ML, Gokhale PC, DeCaprio JA.

Proc Natl Acad Sci U S A. 2019 Jan 15;116(3):1027-1032. doi: 10.1073/pnas.1818798116. Epub 2018 Dec 31.

9.

The kinases IKBKE and TBK1 regulate MYC-dependent survival pathways through YB-1 in AML and are targets for therapy.

Liu S, Marneth AE, Alexe G, Walker SR, Gandler HI, Ye DQ, Labella K, Mathur R, Toniolo PA, Tillgren M, Gokhale PC, Barbie D, Mullally A, Stegmaier K, Frank DA.

Blood Adv. 2018 Dec 11;2(23):3428-3442. doi: 10.1182/bloodadvances.2018016733.

10.

Recurrent ubiquitin B silencing in gynecological cancers establishes dependence on ubiquitin C.

Kedves AT, Gleim S, Liang X, Bonal DM, Sigoillot F, Harbinski F, Sanghavi S, Benander C, George E, Gokhale PC, Nguyen QD, Kirschmeier PT, Distel RJ, Jenkins J, Goldberg MS, Forrester WC.

J Clin Invest. 2017 Dec 1;127(12):4554-4568. doi: 10.1172/JCI92914. Epub 2017 Nov 13.

11.

Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids.

Jenkins RW, Aref AR, Lizotte PH, Ivanova E, Stinson S, Zhou CW, Bowden M, Deng J, Liu H, Miao D, He MX, Walker W, Zhang G, Tian T, Cheng C, Wei Z, Palakurthi S, Bittinger M, Vitzthum H, Kim JW, Merlino A, Quinn M, Venkataramani C, Kaplan JA, Portell A, Gokhale PC, Phillips B, Smart A, Rotem A, Jones RE, Keogh L, Anguiano M, Stapleton L, Jia Z, Barzily-Rokni M, Cañadas I, Thai TC, Hammond MR, Vlahos R, Wang ES, Zhang H, Li S, Hanna GJ, Huang W, Hoang MP, Piris A, Eliane JP, Stemmer-Rachamimov AO, Cameron L, Su MJ, Shah P, Izar B, Thakuria M, LeBoeuf NR, Rabinowits G, Gunda V, Parangi S, Cleary JM, Miller BC, Kitajima S, Thummalapalli R, Miao B, Barbie TU, Sivathanu V, Wong J, Richards WG, Bueno R, Yoon CH, Miret J, Herlyn M, Garraway LA, Van Allen EM, Freeman GJ, Kirschmeier PT, Lorch JH, Ott PA, Hodi FS, Flaherty KT, Kamm RD, Boland GM, Wong KK, Dornan D, Paweletz CP, Barbie DA.

Cancer Discov. 2018 Feb;8(2):196-215. doi: 10.1158/2159-8290.CD-17-0833. Epub 2017 Nov 3.

12.

Inhibition of USP10 induces degradation of oncogenic FLT3.

Weisberg EL, Schauer NJ, Yang J, Lamberto I, Doherty L, Bhatt S, Nonami A, Meng C, Letai A, Wright R, Tiv H, Gokhale PC, Ritorto MS, De Cesare V, Trost M, Christodoulou A, Christie A, Weinstock DM, Adamia S, Stone R, Chauhan D, Anderson KC, Seo HS, Dhe-Paganon S, Sattler M, Gray NS, Griffin JD, Buhrlage SJ.

Nat Chem Biol. 2017 Dec;13(12):1207-1215. doi: 10.1038/nchembio.2486. Epub 2017 Oct 2.

13.

Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model.

Reardon DA, Gokhale PC, Klein SR, Ligon KL, Rodig SJ, Ramkissoon SH, Jones KL, Conway AS, Liao X, Zhou J, Wen PY, Van Den Abbeele AD, Hodi FS, Qin L, Kohl NE, Sharpe AH, Dranoff G, Freeman GJ.

Cancer Immunol Res. 2016 Feb;4(2):124-35. doi: 10.1158/2326-6066.CIR-15-0151. Epub 2015 Nov 6.

14.

Discovery of novel insulin-like growth factor-1 receptor inhibitors with unique time-dependent binding kinetics.

Jin M, Petronella BA, Cooke A, Kadalbajoo M, Siu KW, Kleinberg A, May EW, Gokhale PC, Schulz R, Kahler J, Bittner MA, Foreman K, Pachter JA, Wild R, Epstein D, Mulvihill MJ.

ACS Med Chem Lett. 2013 May 23;4(7):627-31. doi: 10.1021/ml400160a. eCollection 2013 Jul 11.

15.

Vitamin E succinate inhibits survivin and induces apoptosis in pancreatic cancer cells.

Patacsil D, Osayi S, Tran AT, Saenz F, Yimer L, Shajahan AN, Gokhale PC, Verma M, Clarke R, Chauhan SC, Kumar D.

Genes Nutr. 2012 Jan;7(1):83-9. doi: 10.1007/s12263-011-0242-x. Epub 2011 Aug 13.

16.

Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin.

Bhagwat SV, Gokhale PC, Crew AP, Cooke A, Yao Y, Mantis C, Kahler J, Workman J, Bittner M, Dudkin L, Epstein DM, Gibson NW, Wild R, Arnold LD, Houghton PJ, Pachter JA.

Mol Cancer Ther. 2011 Aug;10(8):1394-406. doi: 10.1158/1535-7163.MCT-10-1099. Epub 2011 Jun 14.

17.

Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors.

Falcon BL, Barr S, Gokhale PC, Chou J, Fogarty J, Depeille P, Miglarese M, Epstein DM, McDonald DM.

Cancer Res. 2011 Mar 1;71(5):1573-83. doi: 10.1158/0008-5472.CAN-10-3126.

18.

Imidazo[1,5-a]pyrazines: orally efficacious inhibitors of mTORC1 and mTORC2.

Crew AP, Bhagwat SV, Dong H, Bittner MA, Chan A, Chen X, Coate H, Cooke A, Gokhale PC, Honda A, Jin M, Kahler J, Mantis C, Mulvihill MJ, Tavares-Greco PA, Volk B, Wang J, Werner DS, Arnold LD, Pachter JA, Wild R, Gibson NW.

Bioorg Med Chem Lett. 2011 Apr 1;21(7):2092-7. doi: 10.1016/j.bmcl.2011.01.139. Epub 2011 Feb 3.

PMID:
21353551
19.

18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer.

McKinley ET, Bugaj JE, Zhao P, Guleryuz S, Mantis C, Gokhale PC, Wild R, Manning HC.

Clin Cancer Res. 2011 May 15;17(10):3332-40. doi: 10.1158/1078-0432.CCR-10-2274. Epub 2011 Jan 21.

20.

Potent and selective cyclohexyl-derived imidazopyrazine insulin-like growth factor 1 receptor inhibitors with in vivo efficacy.

Jin M, Kleinberg A, Cooke A, Gokhale PC, Foreman K, Dong H, Siu KW, Bittner MA, Mulvihill KM, Yao Y, Landfair D, O'Connor M, Mak G, Pachter JA, Wild R, Rosenfeld-Franklin M, Ji Q, Mulvihill MJ.

Bioorg Med Chem Lett. 2011 Feb 15;21(4):1176-80. doi: 10.1016/j.bmcl.2010.12.094. Epub 2010 Dec 23.

PMID:
21251824
21.

Discovery of an Orally Efficacious Imidazo[5,1-f][1,2,4]triazine Dual Inhibitor of IGF-1R and IR.

Jin M, Gokhale PC, Cooke A, Foreman K, Buck E, May EW, Feng L, Bittner MA, Kadalbajoo M, Landfair D, Siu KW, Stolz KM, Werner DS, Laufer RS, Li AH, Dong H, Steinig AG, Kleinberg A, Yao Y, Pachter JA, Wild R, Mulvihill MJ.

ACS Med Chem Lett. 2010 Aug 30;1(9):510-5. doi: 10.1021/ml100178g. eCollection 2010 Dec 9.

22.

Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer.

Buck E, Gokhale PC, Koujak S, Brown E, Eyzaguirre A, Tao N, Rosenfeld-Franklin M, Lerner L, Chiu MI, Wild R, Epstein D, Pachter JA, Miglarese MR.

Mol Cancer Ther. 2010 Oct;9(10):2652-64. doi: 10.1158/1535-7163.MCT-10-0318. Epub 2010 Oct 5.

23.

Systemic delivery and pre-clinical evaluation of nanoparticles containing antisense oligonucleotides and siRNAs.

Zhang C, Newsome JT, Mewani R, Pei J, Gokhale PC, Kasid UN.

Methods Mol Biol. 2009;480:65-83. doi: 10.1007/978-1-59745-429-2_5.

PMID:
19085118
24.

Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.

Zhang C, Pei J, Kumar D, Sakabe I, Boudreau HE, Gokhale PC, Kasid UN.

Methods Mol Biol. 2007;361:163-85. Review.

PMID:
17172711
25.

Expression of BRCC3, a novel cell cycle regulated molecule, is associated with increased phospho-ERK and cell proliferation.

Boudreau HE, Broustas CG, Gokhale PC, Kumar D, Mewani RR, Rone JD, Haddad BR, Kasid U.

Int J Mol Med. 2007 Jan;19(1):29-39.

PMID:
17143545
26.

Combined transcriptional and translational targeting of EWS/FLI-1 in Ewing's sarcoma.

Mateo-Lozano S, Gokhale PC, Soldatenkov VA, Dritschilo A, Tirado OM, Notario V.

Clin Cancer Res. 2006 Nov 15;12(22):6781-90.

27.

Interaction and stabilization of X-linked inhibitor of apoptosis by Raf-1 protein kinase.

Tian S, Mewani RR, Kumar D, Li B, Danner MT, Ahmad I, Rahman A, Notario V, Dritschilo A, Kasid UN, Gokhale PC.

Int J Oncol. 2006 Oct;29(4):861-7.

PMID:
16964381
28.

Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies.

Dritschilo A, Huang CH, Rudin CM, Marshall J, Collins B, Dul JL, Zhang C, Kumar D, Gokhale PC, Ahmad A, Ahmad I, Sherman JW, Kasid UN.

Clin Cancer Res. 2006 Feb 15;12(4):1251-9.

29.

Gene expression profile by inhibiting Raf-1 protein kinase in breast cancer cells.

Mewani RR, Tian S, Li B, Danner MT, Carr TD, Lee S, Rahman A, Kasid UN, Jung M, Dritschilo A, Gokhale PC.

Int J Mol Med. 2006 Mar;17(3):457-63.

PMID:
16465392
30.

Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study.

Rudin CM, Marshall JL, Huang CH, Kindler HL, Zhang C, Kumar D, Gokhale PC, Steinberg J, Wanaski S, Kasid UN, Ratain MJ.

Clin Cancer Res. 2004 Nov 1;10(21):7244-51.

31.

BRCC2, a novel BH3-like domain-containing protein, induces apoptosis in a caspase-dependent manner.

Broustas CG, Gokhale PC, Rahman A, Dritschilo A, Ahmad I, Kasid U.

J Biol Chem. 2004 Jun 18;279(25):26780-8. Epub 2004 Apr 6.

32.
33.
34.

Pharmacokinetics, toxicity, and efficacy of ends-modified raf antisense oligodeoxyribonucleotide encapsulated in a novel cationic liposome.

Gokhale PC, Zhang C, Newsome JT, Pei J, Ahmad I, Rahman A, Dritschilo A, Kasid UN.

Clin Cancer Res. 2002 Nov;8(11):3611-21.

35.

A comparative study of plasma concentrations of liposomal amphotericin B (L-AMP-LRC-1) in adults, children and neonates.

Kotwani RN, Gokhale PC, Bodhe PV, Kirodian BG, Kshirsagar NA, Pandya SK.

Int J Pharm. 2002 May 15;238(1-2):11-5.

PMID:
11996806
36.

Safety and efficacy of liposomal amphotericin B in patients with cryptococcal meningitis.

Kotwani RN, Gokhale PC, Bodhe PV, Kirodian BG, Kshirsagar NA.

J Assoc Physicians India. 2001 Nov;49:1086-90.

PMID:
11868862
37.

Improved safety, pharmacokinetics and therapeutic efficacy profiles of a novel liposomal formulation of mitoxantrone.

Gokhale PC, Pei J, Zhang C, Ahmad I, Rahman A, Kasid U.

Anticancer Res. 2001 Sep-Oct;21(5):3313-21.

PMID:
11848489
38.

Antisense raf oligodeoxyribonucleotide is a radiosensitizer in vivo.

Gokhale PC, McRae D, Monia BP, Bagg A, Rahman A, Dritschilo A, Kasid U.

Antisense Nucleic Acid Drug Dev. 1999 Apr;9(2):191-201.

PMID:
10355825
39.

Comparative in vivo studies with paclitaxel and liposome-encapsulated paclitaxel.

Cabanes A, Briggs KE, Gokhale PC, Treat JA, Rahman A.

Int J Oncol. 1998 May;12(5):1035-40.

PMID:
9538125
41.

An improved method of encapsulation of doxorubicin in liposomes: pharmacological, toxicological and therapeutic evaluation.

Gokhale PC, Radhakrishnan B, Husain SR, Abernethy DR, Sacher R, Dritschilo A, Rahman A.

Br J Cancer. 1996 Jul;74(1):43-8.

42.

Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B (L-AmpB-LRC) in a child.

Karande SC, Boby KF, Lahiri KR, Jain MK, Kshirsagar NA, Gokhale PC, Pandya SK.

Trop Doct. 1995 Apr;25(2):80-1. No abstract available.

PMID:
7778200
43.

Liposomes as drug delivery system in leishmaniasis.

Kshirsagar NA, Gokhale PC, Pandya SK.

J Assoc Physicians India. 1995 Jan;43(1):46-8. Review. No abstract available.

PMID:
9282640
44.

Treatment of candiduria with liposomal amphotericin B (L-AmpB-LRC) in children.

Gokhale PC, Kshirsagar NA, Khan MU, Pandya SK, Merchant RH, Mehta KP, Colaco MP.

J Antimicrob Chemother. 1994 Apr;33(4):889-91. No abstract available.

PMID:
8056715
45.

Successful treatment of resistant visceral leishmaniasis with liposomal amphotericin B.

Gokhale PC, Kshirsagar NA, Khan MU, Pandya SK, Meisheri YV, Thakur CP, Choudhary CB.

Trans R Soc Trop Med Hyg. 1994 Mar-Apr;88(2):228. No abstract available.

PMID:
8036684
46.

Pharmacokinetics and tolerance of liposomal amphotericin B in patients.

Gokhale PC, Barapatre RJ, Advani SH, Kshirsagar NA, Pandya SK.

J Antimicrob Chemother. 1993 Jul;32(1):133-9.

PMID:
8226404
47.

Preclinical & pharmaceutical testing of liposomal amphotericin B.

Gokhale PC, Kotwani RN, Dange SY, Kshirsagar NA, Pandya SK.

Indian J Med Res. 1993 Apr;98:75-8.

PMID:
8344735
48.

Successful treatment of disseminated candidiasis resistant to amphotericin B by liposomal amphotericin B: a case report.

Gokhale PC, Barapatre RJ, Advani SH, Kshirsagar NA, Pandya SK.

J Cancer Res Clin Oncol. 1993;119(10):569-71.

PMID:
8335676
49.

Analysis of a clinically important interaction between phenytoin and Shankhapushpi, an Ayurvedic preparation.

Dandekar UP, Chandra RS, Dalvi SS, Joshi MV, Gokhale PC, Sharma AV, Shah PU, Kshirsagar NA.

J Ethnopharmacol. 1992 Jan;35(3):285-8.

PMID:
1548901
50.

Bioinequivalence of marketed diltiazem preparations.

Joshi MV, Gokhale PC, Pohujani SM, Dalvi SS, Karandikar SM, Kshirsagar NA.

Eur J Clin Pharmacol. 1990;39(2):189-90.

PMID:
2253673

Supplemental Content

Loading ...
Support Center